# A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery

> **NCT03804125** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Cerebral Stroke
- Thrombosis, Deep Vein
- Pulmonary Embolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03804125
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision to not conduct the study and was cancelled prior to any enrollment.
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03804125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03804125, "A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03804125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*